Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1040588 | 0.81 | NOS2 (0.50) | CES2CES1AKR1B1KEAP1GRIN1 | |
| SCHEMBL689470 | 0.81 | GRIN2B (0.50) | CES2CES1AKR1B1GRIN1GRIN2B | |
| SCHEMBL8013340 | 0.79 | CES1 (0.54) | CES2CES1AKR1B1CTBP2ALDH1A1 | |
| SCHEMBL3240431 | 0.79 | GRIN1 (0.48) | CES2CES1AKR1B1GRIN1GRIN2B | |
| SCHEMBL3686805 | 0.79 | NOS2 (0.44) | CES2CES1AKR1B1KEAP1GRIN1 | |
| SCHEMBL817534 | 0.78 | NOS2 (0.42) | CES2CES1AKR1B1KEAP1GRIN1 | |
| SCHEMBL10332488 | 0.78 | ALDH1A1 (0.42) | CES2CES1AKR1B1KEAP1GRIN1 | |
| SCHEMBL818281 | 0.78 | L3MBTL1 (0.42) | CES2CES1AKR1B1KEAP1GRIN1 | |
| SCHEMBL817467 | 0.78 | NOS2 (0.42) | CES2CES1AKR1B1KEAP1GRIN1 | |
| SCHEMBL816881 | 0.78 | NOS2 (0.42) | CES2CES1AKR1B1KEAP1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | claimed |
| US-6677344-B2 | Chymase inhibitor for the treatment of eosinophilia | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-01-13 | — | — | US | claimed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | claimed |
| EP-1089752-A4 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-01-02 | — | — | EP | claimed |
| EP-1089752-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1999062538-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-12-09 | — | — | WO | claimed |
| EP-0400290-A1 | 5-Amino-4-hydroxyvalerianic acid derivatives useful as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | claimed |
| EP-0329606-A2 | Antibiotics from myxocuccos | CIBA-GEIGY AG (CH) | 1989-08-23 | — | — | EP | claimed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | claimed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | claimed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| EP-2170076-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| WO-2009002495-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
| EP-0056408-A1 | GUANYLATED AMINOGLYCOSIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANDOZ AG (CH) | 1982-07-28 | — | — | EP | disclosed |
| WO-1982000464-A1 | GUANYLATED AMINOGLYCOSIDES,A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | LOIBNER H | 1982-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | CES2 1831/4885CES1 986/4885AKR1B1 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.